Vaderis
The startup develops an oral medication specifically for treating hereditary hemorrhagic telangiectasia (HHT), a rare disease characterized by vascular malformations. This treatment alleviates symptoms and decreases the formation of new lesions, enabling healthcare providers to manage disease progression effectively.
Traction –/10
Basel, Switzerland · HQ
- Biotechnology
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops an oral medication specifically for treating hereditary hemorrhagic telangiectasia (HHT), a rare disease characterized by vascular malformations. This treatment alleviates symptoms and decreases the formation of new lesions, enabling healthcare providers to manage disease progression effectively.